GeoVax Labs, Inc.
GOVXNasdaq
$0.97
↑ +11.9%Jul 17 close · end-of-day
Price
1Y↓ -94.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$852,282.00
Net Income (TTM)
-$21.4M
Free Cash Flow (TTM)
-$19.1M
Gross Margin
—
Operating Margin
-2523.4%
Net Margin
-2507.3%
ROE
-4327.7%
ROIC
—
Debt / Equity
—
Net Cash
$1.3M
Return 1Y
-94.7%
Company profile
GeoVax Labs, Inc. develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV) and malaria.
- CEO
- David A. Dodd
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Georgia
- Website
- geovax.com
Earnings
GOVX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.8M | $385,501.00 | $81,526.00 | $0.00 | $4.0M | $2.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$2.8M | -$18.7M | -$14.0M | -$26.7M | -$25.1M | -$21.6M |
| Net income | -$3.0M | -$18.6M | -$14.0M | -$26.0M | -$25.0M | -$21.5M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$2.8M | -$11.2M | -$19.0M | -$25.2M | -$24.7M | -$21.5M |
| Free cash flow | -$2.9M | -$11.2M | -$19.2M | -$25.2M | -$24.7M | -$21.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -154.5% | -4862.7% | -17207.5% | — | -635.8% | -869.3% |
| Net margin | -162.2% | -4817.2% | -17198.3% | — | -632.0% | -862.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $300,677.00 | $2.8M | $864,415.00 | $1.6M | $852,282.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.1M | -$5.9M | -$8.3M | -$5.4M | -$5.4M | -$6.4M | -$4.4M | -$5.3M |
| Net income | -$5.1M | -$5.8M | -$8.3M | -$5.4M | -$5.4M | -$6.3M | -$4.4M | -$5.3M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$1.9M | -$9.3M | -$7.8M | -$6.0M | -$4.3M | -$6.2M | -$5.0M | -$3.5M |
| Free cash flow | -$1.9M | -$9.3M | -$7.8M | -$6.0M | -$4.3M | -$6.2M | -$5.0M | -$3.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1683.6% | -209.9% | -965.3% | -330.2% | -635.8% | — | — | — |
| Net margin | -1684.2% | -208.5% | -955.9% | -327.3% | -630.0% | — | — | — |
Company news
Jun 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-17 | SPENCER JOHN N JR | Buy | 10,000 | $0.55 | $5,498.00 | filing |
| 2025-08-07 | McKee Kelly T. Jr.· Chief Medical Officer | Buy | 1,107 | $0.67 | $741.69 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.